1 mL BAC
5 units
resulting U-100 draw
- Concentration
- 10 mg/mL
- BAC added
- 1 mL
BlendInvestigationalPhase 3Moderate confidenceSourced
Cagrilintide and semaglutide
An investigational fixed-ratio combination studied through phase 3 under sponsor-controlled protocols. The programme does not validate mixing separate consumer vials.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
REDEFINE 1 phase 3
Weekly co-formulation quantities
Each dot shows cagrilintide plus semaglutide. Arithmetic uses their combined mass only for a hypothetical 1:1 blend; it cannot establish formulation equivalence.
Maximum study quantity
Up to 2.4 + 2.4 mg weekly
Choose the maximum shown by the evidence line. Any earlier point can be selected below for its arithmetic.Assigned weekly quantities
Select a point for its calculation examples- Weeks 1 to 40.25 + 0.25 mg
- Weeks 5 to 80.5 + 0.5 mg+0.25 mg of each component after 4 weeks
- Weeks 9 to 121 + 1 mg+0.5 mg of each component after 4 weeks
- Weeks 13 to 161.7 + 1.7 mg+0.7 mg of each component after 4 weeks
- Weeks 17 to 682.4 + 2.4 mg+0.7 mg of each component after 4 weeks
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 0.25 + 0.25 mg study quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw15 U
20-30 U reference band
2 mL BAC
10 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 2 mL
3 mL BAC
15 units
resulting U-100 draw
- Concentration
- 3.333 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human StudySubcutaneousOnce weekly
Adults with overweight or obesity enrolled in REDEFINE 1
Each component progressed through 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg once weekly, with four weeks at each escalation stage
The phase 3 product was a fixed-ratio co-formulation. The quantities do not validate combining two separately sourced vials.
View sourceCommunity GuideSubcutaneous in reportOnce weekly
online research community mixed-vial example
A reported 1:1 mixed vial used 0.25 mg cagrilintide plus 0.25 mg semaglutide once weekly
This is community vial arithmetic, not the sponsor's fixed-ratio co-formulation. The archive does not validate compatibility, stability, sterility or clinical equivalence; refined/09-glp1-stacking-community-insights.md:126-133.
View sourceCommunity GuideSubcutaneous in reportsOnce weekly
authenticated research-forum (Peppys) CagriSema and cagrilintide reports
No dedicated CagriSema protocol was captured; the actionable consensus concerns the cagrilintide component, described as very strong and typically begun around 0.25-0.6 mg once weekly, while whole-CagriSema use is reported near 1 mg per week with marked fatigue at higher amounts. Reports repeatedly caution against buying CagriSema premixed in a single vial because the two compounds are said to need different pH, so they are bought and stored separately
Forum provenance from an authenticated archive with usernames and post numbers omitted. There is no curated combination protocol; firm numbers exist mainly for the cagrilintide component and the sponsor trial. Fatigue is the dominant reported side effect and its source (semaglutide versus cagrilintide) is disputed. These quantities are community provenance, not the sponsor's fixed-ratio co-formulation.
View sourceEvidence summary
The combination has been studied as a sponsor-developed clinical formulation. Controlled manufacture, compatibility testing and trial monitoring are part of that evidence.
Calculator boundary
RetaCalc can verify arithmetic for a hypothetical blend. It cannot show that two formulations are compatible, stable, sterile or clinically equivalent to CagriSema.
Community provenance (Peppys)
An authenticated research-forum archive contains no dedicated CagriSema protocol; its usable detail concerns the cagrilintide component, described as very strong and generally begun around a quarter to six-tenths of a milligram once weekly, with whole-CagriSema use reported near 1 mg per week and heavier fatigue at higher amounts. A recurring, emphatic point is that CagriSema should not be bought premixed in a single vial, because the two compounds are said to require different pH and the manufacturer keeps them in separate chambers, so researchers buy and store them separately. Reported quantities conflict, fatigue is the dominant side effect with its source disputed, and usernames and post numbers are omitted. These figures are community provenance and do not validate mixing separate vials.
Warnings and contraindications
A clinical combination product is not equivalent to mixing two separately sourced vials.
Additive gastrointestinal effects and formulation compatibility require formal study.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.